Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

ABVC BioPharma Receives Taiwan Science Park Administration's Approval for GMP Production Facility Plan

Friday, August 04, 2023

ABVC BioPharma has received approval from the Science Park Administration in Taiwan to establish a pilot Good Manufacturing Practise (GMP) facility. This facility will be dedicated to producing Vitargus®, an innovative product used in retinal detachment surgery.

In addition to production, ABVC BioPharma will focus on refining their manufacturing processes for optimal efficiency. The joint effort between ABVC's Taiwan affiliate and co-development partner, BioFirst Corporation focuses on the enhancement of manufacturing processes for Vitargus®. 

Vitargus®, a cutting-edge Vitreous Substitute, represents the first biodegradable hydrogel product intended for use in retinal detachment surgery. Having successfully concluded a feasibility study in Australia, Vitargus® received approval from the Australian Therapeutic Goods Administration (TGA) to proceed with the next phase of trials.

The focus on enhancing the facility's infrastructure is to yield substantial reductions in ongoing trial expenses, optimise production processes, kerbing costs linked to outsourcing to external Contract Research Organisations (CROs), and ensuring heightened operational efficiency.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024